Xencor, Inc. (NASDAQ:XNCR - Get Free Report) rose 6.3% on Tuesday . The company traded as high as $9.98 and last traded at $10.15. Approximately 24,532 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 664,849 shares. The stock had previously closed at $9.55.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the company. Wall Street Zen lowered Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company dropped their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Wedbush reiterated an "outperform" rating and issued a $31.00 target price on shares of Xencor in a research note on Wednesday, April 30th. Barclays dropped their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday, May 8th. Finally, William Blair assumed coverage on Xencor in a research note on Monday, April 21st. They issued an "outperform" rating for the company. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $29.50.
Get Our Latest Report on Xencor
Xencor Price Performance
The stock has a market cap of $654.06 million, a PE ratio of -2.87 and a beta of 0.87. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The business has a fifty day moving average of $9.06 and a 200 day moving average of $15.18.
Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). The business had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company's revenue for the quarter was up 104.6% on a year-over-year basis. During the same period in the prior year, the company posted ($1.11) EPS. Sell-side analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.
Insiders Place Their Bets
In other Xencor news, EVP Nancy Valente sold 4,616 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the transaction, the executive vice president now owns 49,169 shares of the company's stock, valued at $542,334.07. This trade represents a 8.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.76% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Inspire Investing LLC lifted its holdings in Xencor by 85.3% during the 1st quarter. Inspire Investing LLC now owns 32,402 shares of the biopharmaceutical company's stock worth $345,000 after buying an additional 14,913 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Xencor by 89.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company's stock worth $7,732,000 after buying an additional 344,088 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company's stock worth $471,000 after buying an additional 3,692 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Xencor by 73.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 904,485 shares of the biopharmaceutical company's stock worth $9,624,000 after buying an additional 384,509 shares during the last quarter. Finally, BVF Inc. IL lifted its holdings in Xencor by 19.7% during the 1st quarter. BVF Inc. IL now owns 2,740,141 shares of the biopharmaceutical company's stock worth $29,155,000 after buying an additional 451,381 shares during the last quarter.
About Xencor
(
Get Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
See Also
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
